復星醫藥(600196.SH):子公司參與研製的YP01001膠囊臨試申請獲受理
格隆匯1月11日丨復星醫藥(600196.SH)宣佈,近日,公司控股子公司重慶藥友製藥有限責任公司收到《受理通知書》,其參與研製的YP01001膠囊用於治療晚期實體瘤(肝癌、胃癌等)獲國家藥監局臨牀試驗註冊審評受理。
該新藥為創新型小分子化學藥物,擬用於治療晚期實體瘤(肝癌、胃癌等);該新藥臨牀前開發由集團與上海藥明康德新藥開發有限公司合作開展、臨牀及以後階段的開發擬由集團自主實施。
截至該公吿日,中國大陸已上市的該新藥同類型藥品有甲磺酸侖伐替尼膠囊等。根據IQVIA CHPA數據,2019年度,甲磺酸侖伐替尼膠囊於中國大陸的銷售額約為人民幣2200萬元。
截至2020年11月,集團現階段針對該新藥累計研發投入約為人民幣3059萬元(未經審計)。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.